Background: MDS FISH was routinely ordered together with chromosome analysis for patients with cytopenia in our hospital. The utility of MDS FISH in the pediatric population is unknown.
and health care costs, with no added benefit to patient care. In our institution, fluorescence in situ hybridization (FISH) and conventional cytogenetics have been included in the standard workup of patients with cytopenia, bone marrow failure syndrome, myelodysplastic syndrome (MDS), and aplastic anemia. Although FISH is a sensitive technique that can be performed on nondividing cells, 1, 2 it only detects a few targeted abnormalities. In contrast, conventional cytogenetics has the ability to detect structural abnormalities over the entire genome. Multiple studies have reported the limited utility of FISH in the diagnosis and followup of myeloid neoplasms. [3] [4] [5] [6] We are interested in determining the utility of FISH in the initial workup and followup in pediatric patients with cytopenia, bone marrow failure syndrome, or MDS. This retrospective study will provide valuable information for physicians by evidence-based guidance in the selection of tests performed on bone marrow for these indications. 
Results
A total of 182 patients (ages range from 8 months to 21 years old) were recruited in the study, with 253 paired MDS FISH and conventional cytogenetic results over a 5-year period. Indications for the MDS FISH and chromosome analysis include 1) history of solid tumor or hematologic malignancies to rule out therapy-related MDS; 2) pancytopenia or bicytopenia; 3) followup for patients with a history of bone marrow failure syndrome; 4) congenital diseases that might be associated with MDS but present with cytopenia; 5) workup for single lineage cytopenia such as anemia, thrombocytopenia, or neutropenia.
We found significant concordance between MDS FISH and chromosome analysis (P < .0001 with Fisher exact test; 
Interventions and Outcome
We presented our results in various clinical team meetings, which showed no added benefit in MDS FISH testing in comparison to chromosome analysis alone. We developed an algorithm with our cytogenetics laboratory to add MDS FISH if the following criteria were met: 1) there is unsatisfactory growth (<20 metaphase harvested or no growth in culture); or 2) to clarify clinically significant abnormalities identified on chromosome analysis. In Phase I, January to July 2015, 7 months, which began after presenting our results at the clinical team meetings, no additional intervention took place. In Phase II, August 2015 to February 2016 (8 months), we initiated a review process in which, prior to being sent, all bone marrow orders would be screened by a hematopathologist (Figure 1) 
Figure 1
The FISH MDS volumes, performed and cancellation rates in the periods indicated. There was no decrease in the volume during the Phase I intervention. After we implemented the Phase II intervention, there was significant reduction in the volume and cancellation rate. The cancellation rate was sustained in the following year.
In the following year (March 2016 to February 2017), 50 MDS FISH orders were made; however, 76% (38) orders were cancelled, a similar cancellation rate to the Phase II period.
These results showed that the pathologist review functioned as a gatekeeper. This information is especially helpful in teaching staff where multiple caregivers place orders via electronic system.
Discussion
Annual spending on health care in the US is estimated to rise by an average of 5.8% through 2024 and to reach one-fifth of the US economy by the same year. 7, 8 Laboratory testing is the highest-volume medical activity and influences medical decisions. 9, 10 Currently, laboratory testing costs comprise 4% of current health care costs, estimated at $60 billion. 11 With advances in technology and personalized medicine, the cost for genetic testing has increased dramatically. 11 Since the top 3 causes of lab-related harm and litigation are inappropriate ordering, misinterpretation, and failure to retrieve laboratory test results, 12 opportunities exist to improve the value of laboratory testing.
13-16
MDS FISH is not included as a recommended test in the diagnosis of primary MDSs in adults, based on recommendations from the European LeukemiaNet. 17 Some studies show the lack of utility of MDS FISH in adult patients. 3, 4 In this study, we looked at the utility of MDS FISH in the workup of pediatric patients with cytopenia, in comparison with conventional cytogenetics alone, since these 2 tests are ordered simultaneously in our hospital. In general, developing an evidence-based test selection process will lead to more effective test utilization and could save millions in estimated annual costs. 22 The need for a standardized approach has been demonstrated by the analysis of the test results and ordered tests, which showed conventional cytogenetics and MDS FISH were highly concordant (P < .0001). We propose that laboratories should establish test-ordering guidelines for certain complex tests to ensure maximum utility. For example, MDS FISH should be added when growth in the culture is unsatisfactory or to clarify clinically significant abnormalities identified by chromosome analysis.
In addition, our experience showed that in order to be effective in optimizing test utilization, an active review process in combination with education is needed. Education alone has not been shown to accomplish this goal. 23 In this study, we showed minimal effect in the test volume reduction in Phase I, which was education alone. Multiple factors contribute to the lack of effectiveness of the initial eduction process. In large academic hospitals, the orders are placed by various caregivers. Also in many institutions, order sets are utilized to simplify ordering for various diseases. Finally, there is, in general, a lack of continued education or monitoring in the clinical services. In our study, we demonstrated that the reduction in MDS FISH volumes was significantly improved only after we implemented the test review process (Phase II). Since the implementation of the review process, test volumes have continued to be reduced. LM
